146 related articles for article (PubMed ID: 11950277)
1. Metallothionein-1+2 deficiency increases brain pathology in transgenic mice with astrocyte-targeted expression of interleukin 6.
Giralt M; Penkowa M; Hernández J; Molinero A; Carrasco J; Lago N; Camats J; Campbell IL; Hidalgo J
Neurobiol Dis; 2002 Apr; 9(3):319-38. PubMed ID: 11950277
[TBL] [Abstract][Full Text] [Related]
2. Metallothionein-I overexpression alters brain inflammation and stimulates brain repair in transgenic mice with astrocyte-targeted interleukin-6 expression.
Penkowa M; Camats J; Giralt M; Molinero A; Hernández J; Carrasco J; Campbell IL; Hidalgo J
Glia; 2003 May; 42(3):287-306. PubMed ID: 12673834
[TBL] [Abstract][Full Text] [Related]
3. Localization of metallothionein-I and -III expression in the CNS of transgenic mice with astrocyte-targeted expression of interleukin 6.
Carrasco J; Hernandez J; Gonzalez B; Campbell IL; Hidalgo J
Exp Neurol; 1998 Oct; 153(2):184-94. PubMed ID: 9784278
[TBL] [Abstract][Full Text] [Related]
4. Astrocyte-targeted expression of interleukin-3 and interferon-alpha causes region-specific changes in metallothionein expression in the brain.
Giralt M; Carrasco J; Penkowa M; Morcillo MA; Santamaría J; Campbell IL; Hidalgo J
Exp Neurol; 2001 Apr; 168(2):334-46. PubMed ID: 11259121
[TBL] [Abstract][Full Text] [Related]
5. Metallothionein prevents neurodegeneration and central nervous system cell death after treatment with gliotoxin 6-aminonicotinamide.
Penkowa M; Quintana A; Carrasco J; Giralt M; Molinero A; Hidalgo J
J Neurosci Res; 2004 Jul; 77(1):35-53. PubMed ID: 15197737
[TBL] [Abstract][Full Text] [Related]
6. Metallothionein-I overexpression decreases brain pathology in transgenic mice with astrocyte-targeted expression of interleukin-6.
Molinero A; Penkowa M; Hernández J; Camats J; Giralt M; Lago N; Carrasco J; Campbell IL; Hidalgo J
J Neuropathol Exp Neurol; 2003 Mar; 62(3):315-28. PubMed ID: 12638735
[TBL] [Abstract][Full Text] [Related]
7. Astrocyte-targeted expression of interleukin-6 protects the central nervous system during neuroglial degeneration induced by 6-aminonicotinamide.
Penkowa M; Camats J; Hadberg H; Quintana A; Rojas S; Giralt M; Molinero A; Campbell IL; Hidalgo J
J Neurosci Res; 2003 Aug; 73(4):481-96. PubMed ID: 12898533
[TBL] [Abstract][Full Text] [Related]
8. Metallothioneins are upregulated in symptomatic mice with astrocyte-targeted expression of tumor necrosis factor-alpha.
Carrasco J; Giralt M; Penkowa M; Stalder AK; Campbell IL; Hidalgo J
Exp Neurol; 2000 May; 163(1):46-54. PubMed ID: 10785443
[TBL] [Abstract][Full Text] [Related]
9. IL-6 deficiency leads to reduced metallothionein-I+II expression and increased oxidative stress in the brain stem after 6-aminonicotinamide treatment.
Penkowa M; Hidalgo J
Exp Neurol; 2000 May; 163(1):72-84. PubMed ID: 10785446
[TBL] [Abstract][Full Text] [Related]
10. Altered central nervous system cytokine-growth factor expression profiles and angiogenesis in metallothionein-I+II deficient mice.
Penkowa M; Carrasco J; Giralt M; Molinero A; Hernández J; Campbell IL; Hidalgo J
J Cereb Blood Flow Metab; 2000 Aug; 20(8):1174-89. PubMed ID: 10950378
[TBL] [Abstract][Full Text] [Related]
11. Profound increase in sensitivity to glutamatergic- but not cholinergic agonist-induced seizures in transgenic mice with astrocyte production of IL-6.
Samland H; Huitron-Resendiz S; Masliah E; Criado J; Henriksen SJ; Campbell IL
J Neurosci Res; 2003 Jul; 73(2):176-87. PubMed ID: 12836160
[TBL] [Abstract][Full Text] [Related]
12. Transgenic mice with astrocyte-targeted production of interleukin-6 are resistant to high-fat diet-induced increases in body weight and body fat.
Hidalgo J; Florit S; Giralt M; Ferrer B; Keller C; Pilegaard H
Brain Behav Immun; 2010 Jan; 24(1):119-26. PubMed ID: 19748567
[TBL] [Abstract][Full Text] [Related]
13. Effect of astrocyte-targeted production of IL-6 on traumatic brain injury and its impact on the cortical transcriptome.
Quintana A; Molinero A; Borup R; Nielsen FC; Campbell IL; Penkowa M; Hidalgo J
Dev Neurobiol; 2008 Feb; 68(2):195-208. PubMed ID: 18000830
[TBL] [Abstract][Full Text] [Related]
14. Metallothionein-I and -III expression in animal models of Alzheimer disease.
Carrasco J; Adlard P; Cotman C; Quintana A; Penkowa M; Xu F; Van Nostrand WE; Hidalgo J
Neuroscience; 2006 Dec; 143(4):911-22. PubMed ID: 17027170
[TBL] [Abstract][Full Text] [Related]
15. Metallothionein-1+2 protect the CNS after a focal brain injury.
Giralt M; Penkowa M; Lago N; Molinero A; Hidalgo J
Exp Neurol; 2002 Jan; 173(1):114-28. PubMed ID: 11771944
[TBL] [Abstract][Full Text] [Related]
16. Strongly compromised inflammatory response to brain injury in interleukin-6-deficient mice.
Penkowa M; Moos T; Carrasco J; Hadberg H; Molinero A; Bluethmann H; Hidalgo J
Glia; 1999 Feb; 25(4):343-57. PubMed ID: 10028917
[TBL] [Abstract][Full Text] [Related]
17. Impaired inflammatory response to glial cell death in genetically metallothionein-I- and -II-deficient mice.
Penkowa M; Giralt M; Moos T; Thomsen PS; Hernández J; Hidalgo J
Exp Neurol; 1999 Mar; 156(1):149-64. PubMed ID: 10192786
[TBL] [Abstract][Full Text] [Related]
18. Neuroprotective effect of erythropoietin, and role of metallothionein-1 and -2, in permanent focal cerebral ischemia.
Wakida K; Shimazawa M; Hozumi I; Satoh M; Nagase H; Inuzuka T; Hara H
Neuroscience; 2007 Aug; 148(1):105-14. PubMed ID: 17624681
[TBL] [Abstract][Full Text] [Related]
19. Temporal control of gene recombination in astrocytes by transgenic expression of the tamoxifen-inducible DNA recombinase variant CreERT2.
Hirrlinger PG; Scheller A; Braun C; Hirrlinger J; Kirchhoff F
Glia; 2006 Jul; 54(1):11-20. PubMed ID: 16575885
[TBL] [Abstract][Full Text] [Related]
20. Mice with GFAP-targeted loss of neurofibromin demonstrate increased axonal MET expression with aging.
Su W; Xing R; Guha A; Gutmann DH; Sherman LS
Glia; 2007 May; 55(7):723-33. PubMed ID: 17348023
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
